Skip to main content

New method to make lung cancer drug trials more successful

Australian researchers have developed a new method for finding participants in clinical trials of lung cancer drugs, it was announced on Wednesday.

Researchers from Melbourne's Walter and Eliza Hall Institute (WEHI) were optimistic that the new recruitment process will boost the success rate of drugs being trialled as treatments for lung squamous cell carcinoma, the second most common type of lung cancer.

By mimicking the complexity of human tumours with a research tool, the scientists were able to identify a "biomarker" which could serve as an indication as to which patients would better respond to certain drugs, Xinhua news agency reported.

Marie-Liesse Asselin-Labat, the lead author of the study, said patients with the biomarker were more likely to respond positively to fibroglast growth factor receptor (FGFR) drugs.

"We found that high levels of the anti-cancer drug's target, FGFR1, in a patient's tumour ribonucleic acid (RNA) were a better predictor of their potential response to the drug than the current tests that are used," Asselin-Labat said on Wednesday.

Ben Solomon, a medical oncologist from the Peter MacCallum Cancer Centre, said the finding meant future clinical trials could be designed to succeed.

"Fewer than 10 per cent of new cancer drugs make it past phase 1 clinical trials. In many cases this isn't because of the drug itself, but because of a limitation in clinical trial design," Solomon said.

"Understanding which patients are most likely to respond to certain drugs in clinical trials is crucial both for patients to receive the best treatment, and for new drugs to make it to the clinic."

"Hopefully these data will help to improve trial outcomes by recruiting patients who otherwise might not have been matched to the right trial for them," Solomon said.

​Source​


ᐧ

Comments

Post a Comment

Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing Wednesday, March 28, 2007 08:00 IST  Seema Thakral Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased ris
Post a Comment
Read more

Contract Research Organization Services (CROs) Market Worth 56.34 Billion USD by 2023

 According to a new market research report "Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023", published by MarketsandMarkets™, the global market is projected to reach USD 56.34 Billion by 2023 from USD 39.13 Billion in 2018, at a CAGR of 7.6%. Continue reading here ᐧ
Post a Comment
Read more

The Connection Between Sedatives and Fractures in Elderly Patients

Johns Hopkins Health Alerts: Prescription Drugs The Connection Between Sedatives and Fractures in Elderly Patients All drugs have potential side effects. Indeed, at some point you've probably squinted down the laundry list of possible side effects on the package insert of your medications. Common drug-related side effects include blurred vision, drowsiness, dizziness, dry mouth, heart palpitations, erectile dysfunction, memory impairment, and nervousness. Fortunately, many of these drug side effects occur in only small numbers of people. Now researchers have called into question the connection between sedatives which can cause dizziness and the potential for falls in elderly patients. They point out that well-meant policies discouraging sedative use in older people to prevent falls and fractures may not be necessary. Starting in 1989, New York State required doctors to fill out prescriptions in triplicate for benzodiazepines, the most widely used class of sedativ
Post a Comment
Read more